Neuropsychology
What is Neuropsychology?
The term neuropsychology is referred broadly to the study of behavior, the mind, and its relationship with the central nervous system. Neuropsychology justifiably regards its legitimate domain as the intervening steps between the abstract levels of representation-hallucinations, delusions, and “pure” psychological phenomena, e.g., memory and attention. Neuropsychology is an amalgam of several fields: psychology, neurology, clinical neurosciences, neurophysiology, psychiatry, statistics, and physiology.
- Experimental neuropsychology is the study of brain-behavior relationships in nonhumans.
- Cognitive neuropsychology is the study of normal cognition in humans.
- Behavioral neuropsychology is the blending of behavioral theory and neuropsychological principles.
- Clinical neuropsychology is the study of brain-behavior relationships in humans.
History of Neuropsychology
The official birth of neuropsychology can be dated to the 1960s when an international specialty journal titled Neuropsychologia started its publication on the International Neuropsychology Symposium. Since its start in the early 1960s, neuropsychology has experienced profound changes in the understanding of the cerebral organization. In the second half of the 20th-century, neuropsychology became an independent scientific discipline, dedicating to the relations between brain lesions and the loss of particular mental abilities.
Technological Progress in Aid of Neuropsychology
Starting from the 1960s, the advances of the born discipline of neuropsychology were helped considerably by technological progress. In the early times, neuropsychologists had to wait for postmortem examinations or to rely on the entry and exit sites of some objects in the skull to obtain direct anatomical evidence for the locus of brain damage. In the case of closed head brain injuries, the neuropsychologist often inferred the locus of damage based on psychological deficits. This situation changed drastically when the invention of X-ray computed tomography (CT) scanning in the 1970s allowed one to see the injured structures of the living brain in a non-invasive manner.
- In the following decades, spectacular advances in the noninvasive imaging of the normal working human brain have been obtained with positron emission tomography (PET) and especially with functional magnetic resonance imaging (fMRI).
- Now, complementary information to the preceding evidence can be obtained with transcranial magnetic stimulation (TMS), which allows temporary functional inactivation of select cortical areas in normal observers during the execution of cognitive tasks.
- Further, the perfection of the classical electroencephalographic and evoked-potentials techniques and the introduction of magnetoencephalography have furnished the possibility to obtain global or local brain correlates of behavioral and mental states.
- Recently, digital computers have enormously facilitated the collection and analysis of behavioral and brain data, and computer science and artificial intelligence (AI) have contributed to neuropsychological progress both practically and theoretically.
Fig.1 Analysis of brain networks from functional and structural neuroimaging data. (Vallar, 2020)
Cognitive Neuropsychiatry
Cognitive neuropsychiatry is a relatively new discipline that aims to further understand psychopathological states via careful analysis of information processing. Cognitive functions can be conceptualized as those processes by which an individual perceives both external and internal stimuli; selects stimuli; records information; forms associations between stimuli and manipulates information; and outputs information. One major thrust in this area is to focus on particular signs and symptoms (e.g., specific delusions) rather than attempt to explain broad illness categories. The features of cognitive neuropsychology are the priority of the theoretical framework in which the cognitive effects of brain lesions are interpreted and the conviction that explanation of human cognition must take place at a level of analysis separate from the brain level.
Fig.2 Dual-representational model of PTSD that combines findings from cognitive psychology and neuroscience. (Hall, 2010)
Neuropsychological Measures
Some commonly used neuropsychological measures in the broad domains of cognitive screening, current and premorbid intelligence, memory, language, visuospatial functioning, attention, and executive functioning will briefly be presented in table 1.
Table 1. Commonly used neuropsychological measures.
Cognitive screening measures | Mini-mental state examination (MMSE) |
CAMCOG | |
Measures of current intellectual ability | The wechsler adult intelligence scale, third edition (WAIS-III) |
Wechsler abbreviated scale of intelligence (WASI) | |
Raven’s progressive matrices | |
Measures of premorbid intellectual ability | The national adult reading test (NART) |
The cambridge contextual reading test (CCRT) | |
The spot the word test (STW) | |
The wechsler test of adult reading (WTAR) | |
Measures of memory | The wechsler memory scale, 3rd edition (WMS-III) |
The auditory verbal learning test (AVLT) | |
The California verbal learning test (CVLT) | |
The rivermead behavioral memory test (RBMT) | |
The rey complex figure test (CFT) | |
The recognition memory test (RMT) | |
The doors and people test | |
Measures of language dysfunction | Naming |
Vocabulary | |
Verbal comprehension | |
Visuoconstructional ability | |
Assessment of attention | The test of everyday attention (TEA) |
Behavioral inattention test (BIT) | |
Executive functioning | Verbal fluency |
Behavioral assessment of the dysexecutive syndrome (BADS) | |
Wisconsin card sorting test (WCST) | |
Stroop test of attentional conflict | |
Hayling and brixton tests |
Current Status and Future Development
Studies of cognitive alterations from brain damage will perhaps continue to occupy a central place on the scene, but progress will inevitably depend on many other experimental and theoretical approaches and combined contributions from all biological sciences, from molecular biology to paleoanthropology, as well as from psychology, from cognitive and computer science, and from philosophy. Future research continues to be performed in both single cases and groups, with any etiology of the disease responsible for the patients’ cognitive deficit, and to benefit from developments of neuroimaging and neurosurgical methods, of procedures of behavioral assessment, such as virtual reality, and data analysis.
With long-term expertise in neuroscience, Creative Biolabs is the ideal partner to provide a wide range of leading technologies and products for our customers worldwide. We are available to support its customer in terms of technical expertise and custom services and products. Please do not hesitate to contact us for more detailed information.
References
- Vallar, G.; Caputi, N. The History of Human Neuropsychology. 2020.
- Hall, J.; et al. Neuropsychology. In Companion to Psychiatric Studies. Churchill Livingstone. 2010, pp. 121-140.
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- NeuroMab™ Anti-EPHB2 Antibody(NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Dental Pulp Stem Cells (Cat#: NRZP-1122-ZP113)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- AAV-mDLX-CRE-tdTomato (Cat#: NRZP-0622-ZP721)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- Dextran-CYanine5.5 (Cat#: NTA-2011-ZP118)
- AAV2/9-hEF1a-DIO-mCherry-P2A-TetTox-WPRE-pA (Cat#: NTA-2012-ZP268)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)